Boston Scientific announces results for fourth quarter and full year 2024

Boston Scientific (BSX) PT Raised to $120 at Jefferies

Jefferies analyst Matthew Taylor raised the price target on Boston Scientific (NYSE: BSX) to $120.00 (from $100.00) while maintaining a Buy rating.

The analyst comments "BSX reported 4Q24 sales of $4.56B, +19.5% organic, vs cons $4.42B and EPS of $0.70 +27% vs cons $0.66. BSX introduced '25 guidance... More

Boston Scientific (BSX) PT Raised to $122 at Citi

Citi analyst Joanna Wuensch raised the price target on Boston Scientific (NYSE: BSX) to $122.00 (from $107.00) while maintaining a Buy rating.

The analyst commment "BSX delivered another strong quarter meaningfully surpassing consensus, with four of the eight segments delivering double-digit growth, including Electrophysiology sales... More

Boston Scientific (BSX) PT Raised to $120 at BTIG

BTIG analyst Marie Thibault raised the price target on Boston Scientific (NYSE: BSX) to $120.00 (from $101.00) while maintaining a Buy rating.

The analyst comments "High-flying BSX reported another strong quarter, posting Q4 revenue of $4.561B (+22.4% rep., +19.5% org.) and adj. EPS of $0.70 (consensus: $4.416B and $0.66), well above its guidance of 14-16% organic sales growth and $0.64-$0.66 adj. EPS. The beat was once again led by Electrophysiology which grew ~172% y/y to $649M (consensus $575M), driven by Farapulse, which surpassed $1B in global revenue in 2024. Watchman grew 20% y/y org. to $413M, above consensus of $406M,... More

Boston Scientific (BSX) Tops Q4 EPS by 4c, Beats on Revenue; Offers FY25 EPS Guidance

Boston Scientific (NYSE: BSX) reported Q4 EPS of $0.70, $0.04 better than the analyst estimate of $0.66. Revenue for the quarter came in at $4.56 billion versus the consensus estimate of $4.41 billion.

GUIDANCE:

Boston Scientific sees FY2025 EPS of $2.80-$2.87, versus the consensus of... More